CE Disclosures and Faculty Information

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Evaluate the results of genomic assays and other patient- and treatment-related factors to personalize adjuvant systemic therapy for individuals with newly diagnosed ER-positive, HER2-negative breast cancer.
  • Individualize the selection and sequence of systemic therapy for patients with ER-positive metastatic breast cancer, considering age, menopausal status, prior treatment course, comorbidities, symptomatology and extent of disease.
  • Develop an evidence-based algorithm for the treatment of advanced hormone receptor-positive pre- and postmenopausal breast cancer, incorporating endocrine therapy and biologic and chemotherapeutic agents.
  • Understand the biologic rationale for and available data with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the potential therapeutic role of these agents in this setting.
  • Recognize the FDA approval of and published safety data with the PI3 kinase inhibitor alpelisib in combination with fulvestrant for patients with advanced HER2-negative breast cancer harboring a PIK3CA mutation.
  • Appraise available data with (neo)adjuvant PARP inhibitors for patients with BRCA mutations and HER2-negative breast cancer, and consider the current and potential role of these agents in clinical decision-making.
  • Appreciate recent FDA approvals of and ongoing clinical research evaluating novel agents and strategies for ER-positive or triple-negative breast cancer, and counsel patients regarding protocol and nonresearch treatment recommendations.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOERPosTNBC21/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/ASCOERPosTNBC21/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOERPosTNBC21/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/ASCOERPosTNBC21.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Matthew P Goetz, MD
  Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD
  Professor of Oncology and Pharmacology
  Director, Mayo Clinic Breast SPORE
  Co-Leader, Women’s Cancer Program
  Mayo Clinic
  Rochester, Minnesota
  
  No relevant conflicts of interest to disclose.
  
  Hope S Rugo, MD
  Professor of Medicine
  Director, Breast Oncology and Clinical Trials Education
  University of California, San Francisco
  Helen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  Consulting Agreement: Samsung Bioepis (limited consulting); Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seagen Inc, Sermonix Pharmaceuticals; Honoraria: Mylan, Puma Biotechnology Inc; Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, MacroGenics Inc, Merck, Mylan, Novartis, Pfizer Inc.
  
  Melinda Telli, MD
  Associate Professor of Medicine
  Stanford University School of Medicine
  Director, Breast Cancer Program
  Stanford Cancer Institute
  Stanford, California
  
  Advisory Committee: AbbVie Inc, Blueprint Medicines, Celgene Corporation, Chinook Therapeutics, Daiichi Sankyo Inc, Immunomedics Inc, Lilly, Natera Inc, OncoSec Medical, Pfizer Inc; Consulting Agreements: Genentech, a member of the Roche Group, Guardant Health, Merck; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biothera Pharmaceuticals Inc, Calithera Biosciences, EMD Serono Inc, Genentech, a member of the Roche Group, Merck, OncoSec Medical, Pfizer Inc, PharmaMar, Tesaro, A GSK Company, Vertex Pharmaceuticals Incorporated; Data and Safety Monitoring Board/Committee: G1 Therapeutics, Immunomedics Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences, Lilly, Merck, Novartis, Puma Biotechnology Inc and Seagen Inc.
  
  Release date: July 2021
  Expiration date: July 2022
  
  After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.